Cantor Fitzgerald raises Cigna stock price target on specialty growth By Investing.com

Cantor Fitzgerald raised its price target on Cigna to $340 from $325 while keeping an Overweight rating, citing undervaluation, Evernorth Specialty & Care upside, and progress in Pharmacy Benefits recovery. Cigna also reported Q1 2026 EPS of $7.79 versus $7.61 expected and revenue of $68.52 billion versus $66.2 billion expected, with Mizuho lifting its target to $330. The stock remains supported by buybacks and improved full-year guidance, though analysts note a lack of a clear near-term catalyst.

Analysis

CI is increasingly a self-help story rather than a macro trade: the valuation already discounts a lot of skepticism, but the next leg up depends on management converting operational cleanup into visible earnings durability. The buyback backdrop matters more than the headline target raise because it mechanically tightens float and can lift EPS even if top-line growth remains middling; that makes the stock more resilient in a flat-to-slow-growth healthcare tape.

The main second-order effect is competitive: as Cigna leans harder into the nongovernment payor mix and specialty/care pharmacy economics, it pressures peers with heavier public-exchange exposure and weaker control over pharmacy spread capture. If the rebate-free and renewal commentary holds, the market may start to re-rate the PBM model from a political liability to a cash-flow annuity, which would also help the broader managed-care complex.

The catalyst gap is still real. Without a near-term investor day or another quarter of clean execution, the stock can stay trapped despite cheapness; the risk is not a business collapse but multiple compression if investors decide 2026 is too far away. The contrarian setup is that consensus may be underestimating how much incremental EPS can come from capital returns and mix shift before any growth acceleration is needed.

Key Decisions for Investors

• Go long CI on pullbacks toward the low-$280s with a 3-6 month horizon; target the $330-$340 range where valuation can compress only modestly if execution remains clean. Risk/reward is attractive because downside is buffered by buybacks and a low multiple.
• Pair trade: long CI / short UNH or ELV for 3-6 months if you want to isolate self-help and buyback support versus slower multiple recovery in the higher-quality but less optionality-rich names. The thesis is CI rerates on incremental clarity while peers are more exposed to de-rating from any policy noise.
• Use call spreads in CI into the next earnings print or investor-day window: buy 6-12 month $300/$340 calls to express upside to consensus catching up while capping premium outlay. This is a cleaner way to play the catalyst deficit than outright stock if timing is uncertain.
• Avoid chasing after sharp up-days; the stock likely needs either another beat/raise or concrete investor-day setup to break out sustainably. If that catalyst slips, expect range-bound trading and use it to accumulate rather than add momentum.